Glaxo Wellcome Inc.

John Mark O'Callaghan

Roger D Tung

David D Deininger

Timothy Mark Willson

Robert Anthony Mook

Istvan Kaldor

David Norman Deaton

Jon Loren Collins

Grady Evan Boswell

Matthew J Sharp

Brad Richard Henke

Marcus Brackeen

Keith Rodgers

Stephen John Rout

Hardew Singh

Stephen McGhie

Jeffrey Edmond Cobb

Greg Alan Erickson

Emile Al-Farhan

Mark Stuart Robertson

A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C,alkyl, C,alkoxy, C,fluoroalkoxy, nitrile, or &mdash;NR,R,where R,and R,are independently hydrogen or C,alkyl; (ii) a 5- or 6-membered hetrocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C,alkylene; (v) &mdash;MC,alkylene or C,alkyleneMC,alkylene, wherein M is O, S, or &mdash;NR,wherein R,represents hydrogen or C,alkyl; (vi) a 5- or 6-membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C,alkyl; and (vii) Het-C,alkylene, wherein Het represents a heterocyclic group as defined in point (vi) above; Alk represents C,alkylene; R,represents hydrogen or C,alkyl; Z is selected from the group consisting of: (viii) &mdash;(C,alkylene) phenyl, which phenyl is optionally substituted by one or more halogen atoms; and (ix) &mdash;NR,R,, wherein R,represents hydrogen or C,alkyl, and R,represents &mdash;Y&mdash;(C&boxH;O)&mdash;T&mdash;R,, or &mdash;Y&mdash;(CH(OH))&mdash;T&mdash;R,.

Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma

An improved process for the synthesis of (3S)-tetrahydro-3-furyl N-&lsqb;(1S,2R)-3 -(4-amino-N-isobutylbenzenesulphonamido)-1-benzyl-2-hydroxypropyl&rsqb;carbamate comprising four steps form the compound of formula A and a novel intermediate thereto.

Process for the synthesis of HIV protease inhibitors

Growing community of inventors

Kent, United Kingdom

John Mark O'Callaghan